Acer Therapeutics Inc

NASDAQ:ACER   3:59:50 PM EDT
1.42
+0.20 (+16.39%)
Products

Acer Therapeutics And Relief Therapeutics Announce Update On U.S. FDA Review Of NDA For Acer-001

Published: 06/21/2022 13:36 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (nda) for Acer-001.
Acer Therapeutics Inc - FDA Has Not Raised Any Approvability Concerns Related to Efficacy, Safety Or Pharmacokinetics of Acer-001.
Acer Therapeutics Inc - FDA Has Not Raised Any Approvability Concerns Related to Efficacy, Safety Or Pharmacokinetics of Acer-001.
Acer Therapeutics Inc - FDA Has Issued a Complete Response Letter Regarding New Drug Application (nda) for Acer-001 (sodium Phenylbutyrate).
Acer Therapeutics Inc - Crl Indicates That FDA Cannot Approve NDA in Its Current Form.
Acer Therapeutics Inc - FDA Requested Additional Existing Nonclinical Information to Be Provided in Resubmission of NDA for Acer-001.